top of page

SOBI003 receives EC orphan designation to treat mucopolysaccharidosis type IIIA

Swedish Orphan Biovitrum AB (Sobi) has secured orphan designation from the European Commission (EC) for its development product candidate SOBI003, a chemically modified human recombinant sulfamidase for the treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome).



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page